2BETA-METHOXYCLOVAN-9ALPHA-OL


Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	CINURJJDMOKVMD-AKIOZOGOSA-N
Smiles	CO[C@H]1CC(C)(C)[C@@H]2CC[C@@]3(C)C[C@]12CC[C@H]3O
InChI	InChI=1S/C16H28O2/c1-14(2)9-13(18-4)16-8-6-12(17)15(3,10-16)7-5-11(14)16/h11-13,17H,5-10H2,1-4H3/t11-,12+,13-,15-,16-/m0/s1

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C16H28O2
Molecular Weight	252.39
AlogP	2.74
Hydrogen Bond Acceptor	2.0
Hydrogen Bond Donor	1.0
Number of Rotational Bond	1.0
Polar Surface Area	29.46
Molecular species	NEUTRAL
Aromatic Rings	0.0
Heavy Atoms	18.0

Assay Description	Organism	Bioactivity
Antifungal activity against Botryotinia fuckeliana KUCC 869 assessed as growth inhibition at 200 ug/ml at 27 to 29 degC after 7 days by agar tube dilution method	Botryotinia fuckeliana	81.0 %
Drug metabolism in Macrophomina phaseolina KUCC 730 assessed as transformation to oxidative metabolite, clovan-2-beta, 9-beta, 13-triol at 600 mg at 29 degC after 6 days by TLC analysis	Macrophomina phaseolina	None
Drug metabolism in Macrophomina phaseolina KUCC 730 assessed as transformation to oxidative metabolite, 2-beta-methoxyclovan-9-alpha-13-diol at 600 mg at 29 degC after 6 days by TLC analysis	Macrophomina phaseolina	None
Drug metabolism in Macrophomina phaseolina KUCC 730 assessed as transformation to oxidative metabolite, clovan-2-beta, 13-diol-9-one at 600 mg at 29 degC after 6 days by TLC analysis	Macrophomina phaseolina	None
Drug metabolism in Macrophomina phaseolina KUCC 730 assessed as transformation to oxidative metabolite, clovan-2-beta, 9-alpha-diol at 600 mg at 29 degC after 6 days by TLC analysis	Macrophomina phaseolina	None
Drug metabolism in Macrophomina phaseolina KUCC 730 assessed as transformation to oxidative metabolite, clovan-2-beta, 9-beta-diol at 600 mg at 29 degC after 6 days by TLC analysis	Macrophomina phaseolina	None
Drug metabolism in Macrophomina phaseolina KUCC 730 assessed as transformation to oxidative metabolite, 2-beta-methoxyclovan-9-one at 600 mg at 29 degC after 6 days by TLC analysis	Macrophomina phaseolina	None
Antifungal activity against Botryotinia fuckeliana UCA 992 assessed as inhibition of radial growth at 100 ug/mL after 6 days relative to control	Botryotinia fuckeliana	60.0 %
Antifungal activity against Botryotinia fuckeliana UCA 992 assessed as inhibition of radial growth at 50 ug/mL after 6 days relative to control	Botryotinia fuckeliana	49.0 %
Antifungal activity against Botryotinia fuckeliana UCA 992 assessed as inhibition of radial growth at 200 ug/mL after 6 days relative to control	Botryotinia fuckeliana	83.0 %

Cross References

Resources	Reference
ChEMBL	CHEMBL508593
PubChem	44584079

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).